# Quest Diagnostics (DGX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/DGX
## Company Profile
- Ticker: DGX
- Exchange: NYSE
- Sector: MedTech
- Location: Secaucus, New Jersey
- Tags: Diagnostics
## Stock Data
- Close: 237.77 USD
- Market cap: 21382122225.64 USD
- Last updated: 2026-08-12
## Business Overview
### Diagnostic Information Services Leader
Quest Diagnostics provides laboratory testing and diagnostic insights to physicians, hospitals, consumers, and population-health partners. Its core value lies in converting testing data into information that supports disease detection, treatment decisions, and health management.
### Consumer Access Channels
Quest is expanding access through questhealth.com, consumer-health services, wearable-device partnerships, and wellness programs. These channels allow individuals and employers to use the company’s laboratory network outside traditional physician-ordered testing workflows.
### Advanced Diagnostics
The Advanced Diagnostics portfolio includes blood-based Alzheimer’s testing and assays in cardiometabolic disease, endocrinology, and liver fibrosis. These higher-value tests extend Quest into areas requiring specialized interpretation and clinical decision support.
### Oncology Testing and Digital Integration
Quest received New York State approval for the Haystack minimal residual disease test and is piloting molecular-testing integration through Flatiron Health’s OncoEMR Molecular Profiling Integration platform. These initiatives extend the company beyond traditional laboratory services into precision oncology and embedded clinical workflows.
### National Laboratory Network
Quest’s scale is built on a broad network of laboratories, patient service centers, logistics, and relationships with physicians and health systems. This infrastructure supports high-volume routine testing while providing a distribution channel for newly introduced advanced diagnostics.
## Why The Stock Is Moving

The latest monitored company update is “Quest Diagnostics Declares Quarterly Cash Dividend.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Quest Diagnostics should be watched for advanced-diagnostics mix, volume trends, and any acquisition or network-expansion step. The next update will help show whether the company is moving from promise to a more de-risked stage of execution. Investors will care less about the label than about whether the platform can keep producing credible next steps.

## Recent News
- 2026-08-12 20:15 EST — [Quest Diagnostics Declares Quarterly Cash Dividend](https://biopharmsignal.com/news/DGX/quest-diagnostics-declares-quarterly-cash-dividend-9b7b314f) — Source: Quest Diagnostics
- 2026-07-30 11:30 EST — [Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics](https://biopharmsignal.com/news/DGX/bacterial-vaginosis-linked-to-increased-sti-co-infection-finds-national-study-of-e9bf30a4) — Source: Quest Diagnostics
- 2026-07-23 10:45 EST — [Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026](https://biopharmsignal.com/news/DGX/quest-diagnostics-reports-second-quarter-2026-financial-results-raises-revenue-a-c3c6c528) — Source: Quest Diagnostics
- 2026-07-10 13:24 EST — [One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns](https://biopharmsignal.com/news/DGX/one-in-five-american-workers-tested-had-a-positive-hair-drug-test-in-2025-signal-cb4ae34e) — Source: Quest Diagnostics
- 2026-07-08 12:52 EST — [Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI](https://biopharmsignal.com/news/DGX/quest-diagnostics-now-the-largest-clinical-reference-lab-to-extend-oncology-test-e734c702) — Source: Quest Diagnostics